Making CBD cheap and abundant is just the beginning of this profit opportunity…

Cannabis has been around for thousands of years.

The first record of this valuable plant dates all the way back to 2700 B.C. when Emperor Shen-Nung of ancient China included cannabis in a medical encyclopedia called the Pen Ts’ao.

Over the next 4,719 years, cannabis would endure countless prohibitions, revivals, and innovations before it reached its status today as the single biggest market to emerge in decades.

I’m talking about global cannabis demand nearing $400 billion and a CBD market nearing $22 billion. That kind of demand is virtually unheard of.

But there’s a problem. Accessing the most valuable parts of this plant is costly. In fact, just one kilogram of pure CBD can cost up to $7,000 to extract.

To meet this staggering demand, medical companies need to produce these compounds in a cost-effective manner that will yield safe, consistent, high-quality results.

And only one company is delivering that path to profits on a silver platter right to you…

Turning a Costly Problem Into a Profitable Solution

The cannabis industry is growing at an unprecedented rate and it needs an innovative new solution that will give companies a cost-effective way to manufacture the plant.

To get CBD from the hemp plant to the end product requires a surprisingly lengthy and complex process, with the possibility for issues to arise nearly every step of the way.

These traditional growing operations (think: fields of hemp and greenhouses of marijuana plants) are also putting a significant strain on local resources.

But with innovators working around the clock to maximize cannabis profits from seed to sale, a breakthrough was bound to happen.

That breakthrough is biosynthesis – and the company that has figured out how to harness its power is working on advancing the medical applications and profit potential of the cannabis plant well beyond its current boundaries…

Biosynthesis Explained: At its core, biosynthesis is a naturally occurring process that uses simple chemical compounds to create more complex compounds. Cannabis companies can use biosynthesis to turn microbes such as yeast into tiny cannabinoid factories. And once the genome of, say, brewer’s yeast has been altered to manufacture a cannabinoid like the rare cannabigerol (CBG) instead of alcohol, these trace cannabinoids can be manufactured very cheaply in vast quantities.

The Real Promise of the Cannabis Plant

Using biosynthesis to manufacture THC and CBD means companies can get significantly more product for significantly less money. It also creates a much more consistent, reliable, and safe end product, which is absolutely critical for pharmaceutical-grade cannabis.

But making THC and CBD cheap and abundant is just the beginning.

The cannabis plant produces over 100 different cannabinoid compounds, each with their own therapeutic properties and potential medical applications just waiting to be discovered.

These rare cannabinoids are powerful but almost impossible to access, with one of the most promising compounds costing $2.1 million per ounce to extract.

And while several companies are looking into how they can use biosynthesis to bring these cannabis compounds to market, only one company has delivered.

This company’s breakthrough biosynthesis technology can bring that $2.1 million price tag down to just $15 per ounce.

It’s a discovery that could completely disrupt a $344 billion industry – and your timing couldn’t be better. Its first shipment is already out the door.

But you need to act fast to take advantage of this remarkable opportunity, because we’re projecting a 7,500% revenue for this tiny $4 company in the coming years.

In other words, if you act now, you could be looking at exponential gains.

Don’t let this once-in-a-lifetime chance slip through your fingers.

Find out how you can capitalize on the only company tapping into the full profit potential of the cannabis plant right here.

Take care,

Don Yocham, CFA
Executive Director, National Institute for Cannabis Investors


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *